Skip to content

The Effect of Low-Intensity Blood Flow Restriction Therapy on the Management of Acute Ankle Sprains

The Effect of Low-Intensity Blood Flow Restriction Therapy on the Management of Acute Ankle Sprains

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05596162
Enrollment
0
Registered
2022-10-27
Start date
2022-10-17
Completion date
2024-12-31
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle Sprain 1St Degree, Ankle Sprain 2Nd Degree, Musculoskeletal Injury

Keywords

blood flow restriction, ankle sprain

Brief summary

The primary objective of this study is to evaluate the feasibility of implementing BFR in the rehabilitation treatment of isolated ankle sprains as well as to evaluate the clinical benefits of BFR when compared to standard treatment. This study will evaluate the efficacy of using BFR therapy for the treatment of acute grade I and II ankle sprains. The investigators will evaluate clinical outcomes of range of motion (ROM) and strength testing of ankle dorsiflexion, plantarflexion, inversion, and eversion. This will be a small, randomized control trial study. The investigators will enroll a total of 40 participants, 20 participants will undergo standard physical therapy for isolated lateral ankle sprains and 20 participants will undergo BFR therapy for an isolated lateral ankle sprain. Patients will be randomized into control and experimental group via block randomization.

Interventions

OTHERBlood Flow Restriction Therapy

Exercise with Blood Flow Restriction

OTHERStandard Physical Therapy

Exercise without Blood Flow Restriction

Sponsors

Vanderbilt University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The assessors will not be aware of group allocation.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients will include English speaking student athletes aged 18 and older with clinical diagnosis of an isolated grade I or II lateral ankle sprain

Exclusion criteria

* History of DVT/PE, clotting disordered, peripheral arterial disease, hypertension (BP\>140/90), coronary artery disease, or pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Time to Return to PlayFrom Time of Injury to 8 weeks after InjuryTime from injury to to when injured ankle regains 90% plantarflexion strength compared to uninjured/contralateral side, using a dynamometer.

Secondary

MeasureTime frameDescription
Pain LevelInitial visit & 1, 2, 4, and 8 weeks after the initial visitPain will be assessed with the Visual Analog Pain Scale (VAS). The minimum and maximum scores are 0 and 10 respectively with higher scores meaning a worse outcome.
Range of MotionInitial visit & 1, 2, 4, and 8 weeks after the initial visitRange of motion of ankle dorsiflexion, plantarflexion, inversion, and eversion. It will be measured from 0 to 360 with higher scores meaning a worse outcome.
Strength TestingInitial visit & 1, 2, 4, and 8 weeks after the initial visitStrength testing of ankle dorsiflexion, plantarflexion, inversion, and eversion. It will be measured from 0 to 5 with higher scores meaning a better outcome.
The Foot and Ankle Ability Measure (FAAM) Patient-Reported ScoreInitial visit & 1, 2, 4, and 8 weeks after the initial visitThe Foot and Ankle Ability Measure (FAAM) will be used to measure self-reported physical function. It will be measured from 0 to 116 with higher scores meaning a better outcome.
Foot and Ankle Outcome Score (FAOS) Patient-Reported ScoreInitial visit & 1, 2, 4, and 8 weeks after the initial visitThe Foot and Ankle Outcome Score (FAOS) will be used to measure self-reported physical function. It will be measured from 0 to 100% with higher scores meaning a better outcome.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026